GlassScriptPhysician profile
Ashley D Przybysz
NPI 1215984034
$2,759.22
in general payments reported to CMS, 2019-2025
31 companies · $607 in 2025
The $607 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $115 · 2021: $439 · 2022: $371 · 2023: $376 · 2024: $424 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.81 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $514.94 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $477.41 | 2019-2025 | |
| Pfizer INC. | $301.18 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $165.62 | 2024-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $164.82 | 2021-2025 | |
| Exeltis, USA INC. | $153.72 | 2022-2025 | Slynd |
| Amgen INC. | $117.50 | 2019-2022 | |
| Coopersurgical, INC. | $113.94 | 2019-2025 | Endosee |
| Hologic Sales and Service, LLC | $103.20 | 2021-2025 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
| Bayer Healthcare Pharmaceuticals INC. | $82.43 | 2019-2025 | |
| Evofem Biosciences, INC. | $67.86 | 2021-2022 | |
| Shield Therapeutics INC | $64.39 | 2023-2025 | Accrufer |
| Amag Pharmaceuticals, INC. | $51.18 | 2019-2020 | |
| Organon LLC | $48.75 | 2021-2025 | Nexplanon |
| Boston Scientific Corporation | $42.43 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $37.45 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $31.87 | 2022 | |
| Novo Nordisk INC | $22.31 | 2019 | |
| Sage Therapeutics, LLC | $21.34 | 2025 | Zurzuvae |
| Lundbeck LLC | $20.33 | 2021 | |
| Provepharm INC. | $17.45 | 2025 | Bludigo |
| Lupin INC. | $16.86 | 2021 | |
| Minerva Surgical, INC | $16.19 | 2025 | |
| Millicent US INC | $15.86 | 2023 | Intrarosa |
| Medtronic, INC. | $14.71 | 2022 | |
| Ethicon US, LLC | $14.48 | 2025 | Enseal, Harmonic |
| Daiichi Sankyo INC. | $12.99 | 2019 | |
| Becton, Dickinson and Company | $12.72 | 2023 | Bd Onclarity |
| Duchesnay USA Incorporated | $12.50 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.59 | 2019 | |
| Merck Sharp & Dohme LLC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Przybysz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.